Charles Zhu, an analyst from LifeSci Capital, maintained the Buy rating on Mersana Therapeutics (MRSN – Research Report). The associated price target remains the same with $3.00.
Charles Zhu’s rating is based on Mersana Therapeutics’ strategic advancements and promising developments in their pipeline. The company has implemented a protocol amendment to address proteinuria issues in their Emi-Le treatment for TNBC, which could enhance treatment efficacy by maintaining dose intensity. This amendment includes using ACE inhibitors and ARBs, along with dose reduction measures, rather than delays, to mitigate proteinuria, which is considered an off-target effect.
Furthermore, Mersana’s position in the competitive landscape is strengthened by Pfizer’s discontinuation of their B7-H4-targeted ADC, making Emi-Le the leading asset with an auristatin payload. The company is also focusing on recruiting patients from tertiary centers, which could provide a steady influx of candidates for their trials. These strategic moves, along with the company’s financial position and management’s confidence in their dosing strategy, contribute to Charles Zhu’s Buy rating for Mersana Therapeutics.